Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Patent metadata

Field	Value
Publication number	US-10858341-B2
Application number	US-202016793923-A
Country	US
Kind code	B2
Filing date	Feb 18, 2020
Priority date	Dec 11, 2016
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.

First claim

We claim:

1. A method of treating a disorder in a human or animal subject comprising administering to the human or animal subject a composition comprising unconjugated methylphenidate, at least one salt thereof, isomer thereof, or mixture thereof,
and a compound, wherein the compound is a conjugate of d- methylphenidate having the following chemical formula:

at least one salt thereof, wherein the disorder is selected from the group consisting of attention-deficit hyperactivity disorder (ADHD) and attention-deficit disorder (ADD) in a human or animal subject.

2. The method of claim 1 , wherein the unconjugated methylphenidate is d-threo-methylphenidate, or a salt thereof, or a mixture thereof.

3. The method of claim 1 , wherein the conjugate has the following structure:

4. The method of claim 1 , wherein the at least one salt of the unconjugated methylphenidate and/or the salt of the compound is at least one pharmaceutically or therapeutically acceptable salt form or salt mixture thereof.

5. The method of claim 4 , wherein the at least one pharmaceutically or therapeutically acceptable salt form is independently selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, martrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate, galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate, hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate, and combinations thereof.

6. The method of claim 5 , wherein the at least one pharmaceutically or therapeutically acceptable salt form of the unconjugated methylphenidate or the compound is independently selected from the group consisting of chloride, hydrochloride, hydrogen carbonate (bicarbonate), iodide, bromide, citrate, acetate, formate, salicylate, hydrogen sulfate (bisulfate), hydroxide, nitrate, hydrogen sulfite (bisulfite), propionate, benzene sulfonate, hypophosphite, phosphate, bromate, iodate, chlorate, fluoride, nitrite, and combinations thereof.

7. The method of claim 1 , wherein the composition is in a dosage form selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a thin strip, an oral thin film (OTF), an oral strip, a rectal film, a syrup, a suspension, and a suppository.

8. The method of claim 1 , wherein the composition is formulated for oral administration.

9. The method of claim 1 , wherein the composition provides a dose amount that is the molar equivalent to a dose from about 0.1 mg to about 500 mg d-methylphenidate hydrochloride per dose.

10. The method of claim 1 , wherein the composition is provided in a unit dose form, blister pack, roll, or bulk bottle.

11. The method of claim 10 , wherein the unit dose form provides an amount of d-methylphenidate that is molar equivalent to about 0.5 mg to about 500 mg d-methylphenidate hydrochloride.

12. The method of claim 1 , wherein the unconjugated methylphenidate contributes an amount of d-threo-methylphenidate active in the range of about 5% to about 95% by weight, and the compound contributes an amount of d-threo-methylphenidate active in the range of about 95% to about 5% by weight, based on the total weight of the d-methylphenidate active in the composition.

13. The method of claim 1 , wherein the composition further comprises one or more excipients or one or more additional pharmaceutically active ingredients.

14. The method of claim 13 , wherein the excipients are selected from the group consisting of antiadherents, binders, coatings, disintegrants, gel forming agents, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents, and sweeteners.

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Chi Guochen

Classifications

• C07D211/34 Primary

  with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• A61P25/36

  Opioid-abuse · CPC title

• A61P25/26

  Psychostimulants, e.g. nicotine, cocaine · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title